Fierce Pharma May 15, 2024
Though Galapagos has undergone plenty of staff shakeups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.
Now, the Belgium-based company is teaming up with the largest blood supply network in the U.S. to help realize its decentralized production ambitions for CAR-T therapies on a national scale.
Late Wednesday, Galapagos unveiled a new pact with Blood Centers of America (BCA), gaining access to the collection and donation network’s 50-plus community blood centers across 43 states to assist with manufacturing of Galapagos’ clinical CAR-T programs in hematology/oncology.
For its decentralized manufacturing approach, Galapagos works...
Today's Sponsors
Today's Sponsor
